AMLX
HEALTHCAREAmylyx Pharmaceuticals Inc
Live · NASDAQ · May 9, Close
What's Moving AMLX Today?
No stock-specific AI insight has been generated for AMLX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$16.06
Fundamentals
Trading
AMLX News
20 articles- Amylyx (AMLX) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- Amylyx Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Amylyx Pharmaceuticals Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Amylyx Pharmaceuticals to Participate in Upcoming Investor ConferencesYahoo Finance·May 6, 2026
- Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric HypoglycemiaYahoo Finance·May 5, 2026
- Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 30, 2026
- Amylyx Pharmaceuticals Sets Up Q3 Phase 3 Avexitide Data Readout, Eyes Potential 2027 LaunchMarketbeat·Apr 15, 2026
- Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 8, 2026
- Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial EnrollmentYahoo Finance·Mar 31, 2026
- Is LUCIDITY Trial Completion in Post-Bariatric Hypoglycemia Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)?Yahoo Finance·Mar 28, 2026
- Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Economic Data ReleasesYahoo Finance·Mar 24, 2026
- Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric HypoglycemiaYahoo Finance·Mar 24, 2026
- Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf.Marketbeat·Mar 11, 2026
- Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ...Yahoo Finance·Mar 5, 2026
- A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Reduced Losses And Late Stage Pipeline ProgressYahoo Finance·Mar 4, 2026
- Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 ReadoutMarketbeat·Mar 4, 2026
- Amylyx Refocuses On Avexatide As LUCIDITY Milestone Raises StakesYahoo Finance·Mar 4, 2026
- Amylyx Pharmaceuticals, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 3, 2026
- Amylyx Pharmaceuticals Q4 Earnings Call HighlightsMarketbeat·Mar 3, 2026
- Amylyx (AMLX) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 3, 2026
All 20 articles loaded
Price Data
52-Week Range
$16.06
Fundamentals
Trading
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc (AMLX) is a pioneering biopharmaceutical company dedicated to creating innovative therapies for neurodegenerative conditions, with a strong emphasis on amyotrophic lateral sclerosis (ALS). The company's lead candidate, AMX0035, showcases a novel neuroprotective mechanism that aims to significantly improve patient outcomes, representing a promising advancement in ALS treatment. With a solid clinical development pipeline and a deep expertise in the nuances of neurological disorders, Amylyx is strategically positioned to address urgent unmet medical needs in ALS and potentially other related diseases, making it a compelling prospect for institutional investors.